Performance
Revenue ($m)
$2,207mOperating profit/(loss) ($m)
$493mCore¹ operating profit ($m)
$508mEBITDA² ($m)
$592mProfit/(loss) to shareholders ($m)
$486mBasic earnings/(loss) per share (cents)
201cCore basic earnings per share³ (cents)
150cDividend per share (cents)
44c- Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 in the Notes to financial statements. A reconciliation from core to reported operating profit is included within the Consolidated income statement in the Financial statements
- EBITDA is earnings before interest, tax, depreciation, amortisation and impairment charges. EBITDA is a non-IFRS measure, see page 30 for a reconciliation to reported IFRS results
- Core basic earnings per share is reconciled to basic earnings per share in Note 15 in the Notes to the financial statements
Five reasons to invest in Hikma
We have a long track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.
1Unique and diversified business model
Our business is uniquely positioned, with three main distinct business segments with strong foundations in the US, MENA and Europe. Our large and broad product portfolio is sold in both the retail and hospital markets.
2Strong market position
We are the third largest generic injectable manufacturer and a top ten generic company overall in the US with an increasing market share. In MENA, we are one of the largest pharmaceutical companies and a ‘partner of choice’.
3Commitment to quality
We have built our reputation on manufacturing high-quality medicines. Quality is embedded in our people, our relationships and our thinking. Our excellent track record of regulatory compliance has made us a trusted partner for our customers and patients.
4Large and growing pipeline
We have a large pipeline, with an increasing proportion of differentiated and complex products. We complement our internal development with partnerships and M&A.
5Cash generation
We have consistently generated strong cash flow. Our disciplined approach to cash management and acquisitions ensures we maintain a strong balance sheet and gives us the financial flexibility to support future growth.
Understanding Hikma
Find out how our business model, strategy and established capabilities support our clear investment proposition
Investors calendar
7 August 2020
2020 Interim Results Announcement
5 November 2020
November Trading Update
Results and presentations
Regulatory news
News feed from the London Stock Exchange's Regulatory News Service.
Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy.